Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories
Detection Principle
ImmunoAssay-Antibody
Target
IgM, IgG, total antibody
Testing Method Category
Mixed
Testing Method
Wantai/ELISA total-Ab, CUH/NOVO in-house ELISA total-Ab, Ortho/Vitros total-Ab, YHLO/iFlash-IgG, Ortho/Vitros-IgG, Siemens/Atellica total-Ab, Roche-Elecsys total-Ab, Abbott-Architect-IgG, Abbott/Alinity-IgG, Diasorin/LiaisonXL-IgG, Siemens/Vista total-Ab, Euroimmun/ELISA-IgG, Snibe/Maglumi-IgG
Testing Method - Additional Info
comparison of 15 commercial and 1 in-house anti-SARS-CoV-2 assays in 16 laboratories
Reported Performance
specificity: ? 99% (All except one), 97.2% (Diasorin/LiaisonXL-IgG ); sensitivity: 96.7% (Wantai/ELISA total-Ab), 96.0% (CUH/NOVO in-house ELISA total-Ab), 95.3% (Ortho/Vitros total-Ab), 94.0% (YHLO/iFlash-IgG), 93.3% (Ortho/Vitros-IgG), 93.2% (Siemens/Atellica total-Ab), 92.7% (Roche-Elecsys total-Ab), 90.0% (Abbott-Architect-IgG), 88.0% (Abbott/Alinity-IgG), 84.6% (Diasorin/LiaisonXL-IgG), 81.0% (Siemens/Vista total-Ab), 78.0% (Euroimmun/ELISA-IgG), 78.0% (Snibe/Maglumi-IgG).
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements